Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: J Pain Symptom Manage. 2008 Apr 14;36(3):289–303. doi: 10.1016/j.jpainsymman.2007.10.005

Figure 2.

Figure 2

Ibandronate therapy has a significant effect on reducing tumor-induced bone destruction at day 10 and day 14 post-tumor injection as assessed by high-resolution faxitron analysis. Sham animals, (A) show no radiographically apparent bone destruction at day 10, whereas sarcoma + vehicle (B) animals show a transition from the radio-opaque bone tissue to a radio-lucent appearance by day 10. Sarcoma + ibandronate (C) animals present a markedly reduced pattern and extent of bone destruction as sarcoma + vehicle animals. Sham-injected mouse femurs (F) present a net maintenance of trabecular bone while 2472 sarcoma-injected femurs (G) display osteolytic resorption of trabecular structure at the distal diaphysis of the femur when analyzed with microCT imaging at day 10 post-tumor injection. Treatment with ibandronate significantly attenuates the loss of trabecular bone when viewed with microCT imaging (G) at day 10 post-tumor injection. Scale bars: A–H; .4mm. AU: .4 OR 4?